论文部分内容阅读
钠-葡萄糖协同转运蛋白2(SGLT-2)是一种跨膜蛋白,主要分布在肾脏近曲小管,将葡萄糖从肾小管液转运入肾小管细胞内,约占肾脏重吸收葡萄糖的90%。SGLT-2抑制剂是治疗糖尿病的新药,可降低SGLT-2活性,减少肾脏对葡萄糖的重吸收量,增加尿糖排出,从而降低血糖。已有的临床试验表明SGLT-2抑制剂dapagliflozin治疗糖尿病有效且安全,患者耐受性良好。SGLT-2抑制剂很可能是未来糖尿病治疗的一个新的突破口。
Sodium-glucose cotransporter 2 (SGLT-2) is a transmembrane protein mainly located in the proximal tubule of the kidney, which transports glucose from the tubule fluid into the tubular cells, accounting for about 90% of the reabsorbed glucose in the kidney. SGLT-2 inhibitor is a new drug for the treatment of diabetes, can reduce the activity of SGLT-2, reduce renal reabsorption of glucose, increase urine sugar discharge, thereby reducing blood sugar. Existing clinical trials show that SGLT-2 inhibitor dapagliflozin is effective and safe in the treatment of diabetes and patients are well tolerated. SGLT-2 inhibitors are likely to be a new breakthrough in the future of diabetes treatment.